Annick Vanclooster1, David Cassiman2, Werner Van Steenbergen3, Dorine W Swinkels4, Mirian C H Janssen5, Joost P H Drenth6, Bert Aertgeerts7, Hub Wollersheim8. 1. Department of Hepatology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Electronic address: Annick.vanclooster@uzleuven.be. 2. Department of Hepatology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Electronic address: david.cassiman@med.kuleuven.be. 3. Department of Hepatology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Electronic address: werner.vansteenbergen@uzleuven.be. 4. Department of Laboratory Medicine, Laboratory of Genetic Endocrine and Metabolic diseases, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Dorine.swinkels@radboudumc.nl. 5. Department of General Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: M.Janssen@aig.umcn.nl. 6. Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: J.Drenth@mdl.umcn.nl. 7. Academic Center for General Practice, KU Leuven, Belgium. Electronic address: bert.aertgeerts@med.kuleuven.be. 8. Academic Center for General Practice, KU Leuven, Belgium; Scientific Institute for Quality of Healthcare, Radboud University Medical Centre, Nijmegen Centre for Evidence-Based Practice, Nijmegen, The Netherlands. Electronic address: Hub.Wollersheim@radboudumc.nl.
Abstract
BACKGROUND AND OBJECTIVES: Hereditary haemochromatosis (HH) is the most prevalent genetic liver disease, with an incidence of 1/200 to 1/400 in the Caucasian population. HH patients are treated by family physicians as well as different specialists. When left untreated or insufficiently treated, the complications can become life threatening. To support and evaluate qualitative care for HH, we evaluated and compared the available structured guidelines on screening, diagnosis and management of HH patients. METHODS: Seven appraisers systematically reviewed the retrieved guidelines. The Appraisal of Guidelines Research and Evaluation II (AGREE II) was used to score and discuss the quality and reach consensus. The content of recommendations and the evidence behind them, were evaluated. RESULTS: Three guidelines, developed by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL) and a DUTCH guideline were found. Fifty-seven percent of the recommendations were not shared between the guidelines, pointing to inconsistency of their content. Only two references supporting the recommendations were shared between all three guidelines. The AASLD guideline contains no information about management and follow-up. Moreover, the methodological quality of the AASLD guideline was rated insufficient, except for 'clarity and presentation' (77%). Applicability of the guidelines was scored very low in all three (AASLD: 31%, EASL: 23%, DUTCH: 35%). The DUTCH guideline was judged best. CONCLUSIONS: Very poor consistency between available guidelines for HH hampers qualitative care and its evaluation. An updated high-quality and evidence-based guideline that covers follow-up and management of patients with HH is needed.
BACKGROUND AND OBJECTIVES:Hereditary haemochromatosis (HH) is the most prevalent genetic liver disease, with an incidence of 1/200 to 1/400 in the Caucasian population. HHpatients are treated by family physicians as well as different specialists. When left untreated or insufficiently treated, the complications can become life threatening. To support and evaluate qualitative care for HH, we evaluated and compared the available structured guidelines on screening, diagnosis and management of HHpatients. METHODS: Seven appraisers systematically reviewed the retrieved guidelines. The Appraisal of Guidelines Research and Evaluation II (AGREE II) was used to score and discuss the quality and reach consensus. The content of recommendations and the evidence behind them, were evaluated. RESULTS: Three guidelines, developed by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL) and a DUTCH guideline were found. Fifty-seven percent of the recommendations were not shared between the guidelines, pointing to inconsistency of their content. Only two references supporting the recommendations were shared between all three guidelines. The AASLD guideline contains no information about management and follow-up. Moreover, the methodological quality of the AASLD guideline was rated insufficient, except for 'clarity and presentation' (77%). Applicability of the guidelines was scored very low in all three (AASLD: 31%, EASL: 23%, DUTCH: 35%). The DUTCH guideline was judged best. CONCLUSIONS: Very poor consistency between available guidelines for HH hampers qualitative care and its evaluation. An updated high-quality and evidence-based guideline that covers follow-up and management of patients with HH is needed.
Authors: Simcha Weissman; Muhammad Aziz; Matthew R Baniqued; Vikas Taneja; Mohammed El-Dallal; Wade Lee-Smith; Sameh Elias; Joseph D Feuerstein Journal: Endosc Int Open Date: 2022-06-10
Authors: Tanja Kovačević; Davorka Vrdoljak; Slavica Jurić Petričević; Ivan Buljan; Dario Sambunjak; Željko Krznarić; Ana Marušić; Ana Jerončić Journal: Int J Environ Res Public Health Date: 2022-08-03 Impact factor: 4.614
Authors: Paul Adams; Albert Altes; Pierre Brissot; Barbara Butzeck; Ioav Cabantchik; Rodolfo Cançado; Sonia Distante; Patricia Evans; Robert Evans; Tomas Ganz; Domenico Girelli; Rolf Hultcrantz; Gordon McLaren; Ben Marris; Nils Milman; Elizabeta Nemeth; Peter Nielsen; Brigitte Pineau; Alberto Piperno; Graça Porto; Dianne Prince; John Ryan; Mayka Sanchez; Paulo Santos; Dorine Swinkels; Emerência Teixeira; Ketil Toska; Annick Vanclooster; Desley White Journal: Hepatol Int Date: 2018-03-27 Impact factor: 6.047